Results 11 to 20 of about 76,229 (261)
Dendrimer-based contrast agents for PET imaging [PDF]
Drug Delivery, 2017 Positron emission tomography (PET) imaging offers physiological and biological information through the in vivo distribution of PET agents for disease diagnosis, therapy monitoring and prognosis evaluation.
Lingzhou Zhao +2 more
doaj +3 more sources
Progress of PET Imaging Agents for Cardiovascular Diseases
Journal of Isotopes, 2018 Positron emission tomography ( PET) imaging has successfully allowed the noninvasive detection of cardiovascular disease and shows good clinical application prospects. Development and translation application of various imaging agents furtherly enable PET
MA Hui1;LIANG Hong1;XU Wan-bang2;TANG Gang-hua1
doaj +2 more sources
On the Dissociation Pathways of Copper Complexes Relevant as Pet Imaging Agents
SSRN Electronic Journal, 2022 Several bifunctional chelators have been synthesized in the last years for the development of new 64Cu-based PET agents for in vivo imaging. When designing a metal-based PET probe, it is important to achieve high stability and kinetic inertness once the radioisotope is coordinated. Different competitive assays are commonly used to evaluate the possible
Uzal-Varela, Rocío +8 more
openaire +4 more sources
Development of [124/125I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
Molecules, 2023 Radioiodinated imaging agents for Aβ amyloid plaque imaging in Alzheimer’s disease (AD) patients have not been actively pursued. Our previous studies employed the “diaza” derivatives [11C]TAZA and [18F]flotaza in order to develop successful positron ...
Thrisha T. Reddy +5 more
doaj +1 more source
Peptide-based PET imaging agent of tumor TIGIT expression
EJNMMI Research, 2023 Abstract Background Accumulating studies have demonstrated that elevated TIGIT expression in tumor microenvironment correlates with better therapeutic response to TIGIT-based immunotherapy in pre-clinical studies. Therefore, a non-invasive method to detect tumor TIGIT expression is crucial to predict the therapeutic ...
Dinghu Weng +5 more
openaire +3 more sources
Research Progress of PET Traces for Alzheimer’s Disease
Journal of Isotopes, 2014 Alzheimer’s disease (AD) is unknown cause progressive degenerative diseases of central nervous system. It is a serious threat to the health of the elderly people. The diagnosis is mainly based on pathological examination after death.
TANG Cai-hua1，2;HU Kong-zhen1;TANG Gang-hua1
doaj +1 more source
Frontiers in Neuroscience, 2022 The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A) allowed for the in vivo detection of synaptic density changes, which are correlated with the progression and severity of a variety of neuropsychiatric diseases. While
Takuya Toyonaga +6 more
doaj +1 more source
Modular strategies for PET imaging agents [PDF]
Current Opinion in Chemical Biology, 2010 In recent years, modular and simplified chemical and biological strategies have been developed for the synthesis and implementation of positron emission tomography (PET) radiotracers. New developments in bioconjugation and synthetic methodologies, in combination with advances in macromolecular delivery systems and gene-expression imaging, reflect a ...
openaire +4 more sources
EJNMMI Research, 2020 Background Mesenchymal stem cells (MSCs) have shown potential for treatment of different diseases. However, their working mechanism is still unknown. To elucidate this, the non-invasive and longitudinal tracking of MSCs would be beneficial.
Sarah Belderbos +10 more
doaj +1 more source
Journal of Integrative Neuroscience, 2023 Computed tomography (CT) and magnetic resonance imaging (MRI) provide key structural information on brain pathophysiology. Positron emission tomography (PET) measures metabolism in the living brain; it plays an important role in molecular neuroimaging ...
Ferdinando Calabria +5 more
doaj +1 more source